Skip to content

Avanos Medical AVNS EBITDA margin

EBITDA margin at other companies

Stryker logo
StrykerSYK
24.6%+4.7pp
Cardinal Health logo
Cardinal HealthCAH
1.3%-0.1pp
Boston Scientific logo
Boston ScientificBSX
25.2%+1.6pp
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
15.7%
Medtronic logo
MedtronicMDT
25.9%-0.4pp
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
31.1%-18.9pp

Other financials

Income statement

See full
Revenue$182.2M+8.8%
Gross profit$94.2M+4.9%
Operating income$8.9M-13.6%
Net income$5.1M-22.7%
EPS (diluted)$0.11-21.4%

Balance sheet

See full
Cash & equivalents$65.6M-32.4%
Total debt$138.4M-1.8%
Total equity$782.1M-6.8%
Total assets$1.1B-5.2%

Cash flow

See full
Operating cash flow-$12.3M-148%
CapEx$4.3M-35.8%
Free cash flow-$16.6M-187%

Valuation

See full
Market cap$1.17B+108%
Enterprise value$1.24B+105%
P/S1.6×+0.8×

Profitability

See full
Gross margin50%-4.6pp
Operating margin-9.1%-4.2pp
Net margin-10.4%-4.7pp
FCF margin1.6%-14.9pp

Returns & leverage

See full
Return on equity-9.2%-3.9pp
Debt / equity0.2×0.0×
Current ratio2.5×-0.1×

Where this comes from

Calculated from Avanos Medical’s reported figures.

Based on trailing twelve months.

The official record: Avanos Medical’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avanos Medical's EBITDA margin?
Avanos Medical (AVNS) reported EBITDA margin of -3.6% in Q1 2026.
How has Avanos Medical's EBITDA margin changed year-over-year?
Avanos Medical's EBITDA margin increased by 92.8% year-over-year, from -50.2% to -3.6%.
What is the long-term trend for Avanos Medical's EBITDA margin?
Over 5 years (2020 to 2025), Avanos Medical's EBITDA margin has grown at a 35.6% compound annual growth rate (CAGR), from -0.8% to -3.6%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.